RE:1 million share cross at $9.25 eomInteresting day for TH with good volume at the close.
If we look back to last March, we closed post Trogarzo approval at $9.25.
Often, drug sales start out slowly and then ramp.
The market took the first 100 patient report as a sign of things to come and bid TH up too quickly.
Now, we have come full circle and are in a stronger position with upcoming catalysts....
(1) continued Trogarzo growth
(2) continued Egrifta growth
(3) NASH results
(4) Scientific data on sorilin based drugs
(5) Suspected NASDAQ listing
Now is the time for real institutions to get behind THs story.
bfw